pharmaniaga®

PRESS RELEASE

FOR IMMEDIATE RELEASE

PHARMANIAGA RECORDS SEVENTH CONSECUTIVE PROFITABLE QUARTER, REINFORCING PATH TO EXIT PN17 STATUS

Key takeaways:

- *Biopharmaceutical segment exceeded RM10 million in vaccine sales, with insulin localisation on track for NPRA submission by year end.*
- *5 new generics launched and 12 product approvals in 2025 enhanced pipeline strength.*
- *Indonesian operations expanded with Palu branch and growing CDMO partnership.*

SHAH ALAM, 13 November 2025 – Pharmaniaga Berhad (Pharmaniaga or the Group) continues to sustain its positive momentum towards exiting PN17 status, marking its seventh consecutive profitable quarter for the period ended 30 September 2025 (Q3 FY2025). This achievement underscores the Group's resilient operational capabilities and steady business recovery trajectory.

For Q3 FY2025, the Group recorded a Profit After Tax (PAT) of RM7.5 million, driven by higher concession volumes, an improved product mix and interest savings following partial repayments of borrowings under its Regularisation Plan (RP), supported by effective inventory management.

The Group posted revenue of RM1.01 billion for the quarter. This performance underscores the Group's resilient operational capabilities and sustained business momentum. Earnings Before Interest, Taxation, Depreciation and Amortisation (EBITDA) stood at RM32.7 million, reflecting solid underlying profitability despite a persistently challenging cost environment.

Overall, the Group delivered improved performance in the third quarter ended 30 September 2025, compared to the prior year, supported by stronger operational capabilities, continued focus on cost optimisation and the absence of one-off item in the current period.

Performance for the nine-month ended 30 September 2025 (9M FY2025)

For the nine-month period ended 30 September 2025 (9M FY2025), Pharmaniaga recorded revenue of RM3.0 billion, a 5.5% increase compared to the corresponding period in the previous financial year. The growth was primarily driven by heightened demand within the concession segment.

The Group remained profitable, posting a PAT of RM42.0 million, supported by higher concession volumes, resilient manufacturing operations, and interest savings from partial repayments of borrowings under its RP, supported by effective inventory management.

Pharmaniaga's key business segments continued to demonstrate stable performance throughout 9M FY2025, demonstrating steady operational progress and the Group's commitment to long-term growth.

Managing Director's Overview

Pharmaniaga Managing Director Dato' Zulkifli Jafar said, "Our results this quarter reflect continued progress in strengthening operational fundamentals and improving efficiency across all business segments. Despite a challenging cost environment, we maintained stable profitability and achieved steady revenue growth.

"The announced Budget 2026 provided renewed optimism for the healthcare sector, with higher allocations for medical supplies and concession operations reinforcing the positive outlook for both our concession and non-concession businesses," he said.

He added that the Group continued to make meaningful headway in the biopharmaceutical segment, with new revenue stream surpassing RM10 million across five vaccine products and the insulin localisation programme on track.

"The pharmaceutical division remains active with new product launches and approvals, with the inclusion of 160 new products to the APPL, bringing to a total of more than 840 products during the year. In addition, five new generic products were launched and twelve product approvals secured to date in 2025, further strengthening the Group's pharmaceutical pipeline.

"The logistics and distribution arm recorded a 14.5% increase in volume sold for the nine-month period ended 30 September 2025 compared to the corresponding period of the previous financial year, reflecting stronger demand across the Group's supply network. To cater for the increase in volume and higher operational activity, the Group continues to optimise costs through digitalisation and operational improvements.

"In Indonesia, our 37th distribution outlet in Palu and the Contract Development and Manufacturing Organisation (CDMO) partnership with a leading pharmacy chain signal strong regional growth momentum.

"With these encouraging developments, Pharmaniaga remains focused on strengthening its core business, expanding biopharmaceutical capabilities and driving sustainable growth across all markets," he concluded.

The continued positive performance serves as a strong testament to the effectiveness of the Group's strategic initiatives and rejuvenation plans implemented under its RP.

These consistent results not only demonstrate improved operational efficiency and financial discipline but also reflect growing market confidence in Pharmaniaga's long-term resilience and recovery strategy, positioning the Group firmly on course to exit PN17 status as scheduled.

-END-

About Pharmaniaga Berhad

Pharmaniaga is the pharmaceutical arm of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the substantial shareholders of the Company. Listed on the Main Market of Bursa Malaysia Securities Berhad, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products. With a vision to be the premier Malaysian pharmaceutical company, its operations are strengthened by five manufacturing plants, as well as extensive logistics and distribution network in Malaysia and Indonesia. Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical industry.

For more information, please visit https://pharmaniaga.com/.

Issued by Imej Jiwa Sdn Bhd on behalf of Pharmaniaga Berhad

For further media inquiries please contact:

Dato' Zuhri Iskandar Kamarzaman (Pharmaniaga)
E-mail: zuhri@pharmaniaga.com
Telephone number: 03-3342 9999 ext. 434

Elizabeth Tan (Imej Jiwa)
E-mail: elizabeth@imejjiwa.com | Mobile: +6012 207 0993